Publication list
2023
2022
Rebenku, I.,
Bartha, F.,
Katona, T.,
Zsebik, B.,
Antalffy, G.,
Takács, L.,
Molnár, B.,
Vereb, G.:
Taking molecular pathology to the next level: whole slide multicolor confocal imaging with the Pannoramic Confocal digital pathology scanner.
Cytom. Part A. [Epub ahead of print] 1-11, 2022.
Journal metrics:
Q1 Cell Biology (2021)
D1 Histology (2021)
D1 Pathology and Forensic Medicine (2021)
2021
Bankó, C.,
Nagy, Z.,
Nagy, M.,
Szemán-Nagy, G.,
Rebenku, I.,
Imre, L.,
Tiba, A.,
Hajdu, A.,
Szöllősi, J.,
Kéki, S.,
Bacsó, Z.:
Isocyanide Substitution in Acridine Orange Shifts DNA Damage-Mediated Phototoxicity to Permeabilization of the Lysosomal Membrane in Cancer Cells.
Cancers (Basel). 13 (22), 1-24, 2021.
Journal metrics:
Q2 Cancer Research
Q1 Oncology
Csomós, I.,
Nagy, P.,
Filep, C.,
Rebenku, I.,
Nizsalóczki, E.,
Kovács, T.,
Vámosi, G.,
Mátyus, L.,
Dóczy-Bodnár, A.:
Opposing Effects of Chelidonine on Tyrosine and Serine Phosphorylation of STAT3 in Human Uveal Melanoma Cells.
Int. J. Mol. Sci. 22 (23), 1-14, 2021.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
2020
Nemes, D.,
Kovács, R.,
Nagy, F.,
Tóth, Z.,
Herczegh, P.,
Borbás, A.,
Kelemen, V.,
Pfliegler, V.,
Rebenku, I.,
Hajdu, P.,
Fehér, P.,
Ujhelyi, Z.,
Fenyvesi, F.,
Váradi, J.,
Vecsernyés, M.,
Bácskay, I.:
Comparative biocompatibility and antimicrobial studies of sorbic acid derivates.
Eur. J. Pharm. Sci. 143 1-9, 2020.
Journal metrics:
Q1 Pharmaceutical Science
Hajdu, T.,
Váradi, T.,
Rebenku, I.,
Kovács, T.,
Szöllősi, J.,
Nagy, P.:
Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains.
Front. Cell. Dev. Biol. 8 1-53, 2020.
Journal metrics:
Q1 Cell Biology
Q1 Developmental Biology
2019
Nagy, F.,
Tóth, Z.,
Bozó, A.,
Czeglédi, A.,
Rebenku, I.,
Majoros, L.,
Kovács, R.:
Fluconazole is not inferior than caspofungin, micafungin or amphotericin B in the presence of 50% human serum against Candida albicans and Candida parapsilosis biofilms.
Med. Mycol. 57 (5), 573-581, 2019.
Journal metrics:
Q2 Infectious Diseases
Q1 Medicine (miscellaneous)
D1 Veterinary (miscellaneous)
updated: 2023-03-19, 01:42
